Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
WSC 2026
Secondary Stroke Prevention in Social Media and the Digital Ecosystem-A Narrative Review in China
To synthesize evidence on how digital platforms influence prevention behaviors in secondary stroke prevention and identify conditions for effective implementation.
- Digital access for SSP is meaningful but uneven
- Content quality is often moderate to low; transparency and actionability are limited
- Caregivers and peers can help, but unmoderated communities may amplify misinformation
- Integration is the key differentiator: digital tools work best inside care delivery
The future of digital SSP is not simply more health content. It is a governed, behavior-oriented, clinically integrated digital ecosystem.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
